Gene therapy is back into play after a decade-long failed deliveries. 2017 was a golden year in gene therapy arena, various companies are aggressively developing gene therapy based treatments targeting life-threatening indications. Spark therapeutics got USFDA approval for the first-ever gene therapy based blindness treatment Luxturna. The therapy will help patients with a faulty gene in DNA i.e. RPE65 gene. The company will insert a functional RPE65 gene into the patients DNA to replace the defective gene resulting in vision restoration. It’s a one-time treatment with a hefty price tag of around USD 1 million making it a long shot for the patients. Luxturna got the approval last month and according to the spark therapeutics the treatment will cost around USD 425000 per injection excluding the cost of operation which will further add around USD 4000 – USD 5000 to the same. For justifying the hefty price tag spark therapeutics stated that “the cost for a lifetime of blindness including lost earnings and caregiver wages can easily exceed $1 million”. Being a breakthrough treatment based on gene therapy Luxturna surely is a hot topic in the pharmaceutical industry with experts analyzing the potential of the therapy and price associated with it.
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Global Top Players in Intraocular Lens (IOL) Market
- Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
- Wearable Technology in Healthcare: Major Benefits and Trends
- World Population Day 2018
- How Metaverse is Set to Transform the Healthcare Dynamics?
Jan 10, 2018 | Reading Time: < 1 minute
Gene Therapy: The Next Milestone in Treati...
Nov 18, 2022
Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or rep...
Zealand Pharma’s Phase III Results of Glep...
Oct 04, 2022
Zealand Pharma Announces the Positive Topline Results from its Phase III trial of Glepaglutide Zealand Pharma A/S, a ...
Sign Up & Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.Join Up Now!
Sign up For Newsletters
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.